Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 121 of the 128 references it cites were found in a registry or an index; 143 of the 228 sources its claims cite were checked for support.
Abstract
Review of major molecular alterations in pancreatic cancer.
Overview
CoChat Summary
TL;DR
This is a narrative review of the roles of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer, emphasizing how their alterations shape tumor biology, prognosis and potential targeted treatment strategies. It argues that molecular profiling can support risk assessment, early detection and more personalized therapy, but also shows that many of these biomarkers still need further validation.
Key findings
- TP53 mutations are reported in 50–90% of pancreatic ductal adenocarcinomas and in 60–70% of cases in another section; they are linked to carcinogenesis, chemotherapy resistance and prognosis. TP53 mutations were also reported across pancreatic lesions, from 9.1% of intermediate-grade IPMNs to 75% of invasive ductal adenocarcinomas.
- CDKN2A alterations are described as common and clinically relevant: somatic mutations are reported in up to 95% of pancreatic tumors, and in TCGA analysis patients with CDKN2A mutations or deep deletions had poorer overall survival and primary therapy outcomes. The paper also states that CDKN2A-inactivated PDAC showed increased sensitivity to paclitaxel and SN-38.
- SMAD4/DPC4 loss is repeatedly associated with worse outcomes and metastasis. In one PDAC cohort of 249 patients, 43% lacked SMAD4 expression and 45% were positive; intact SMAD4 expression was associated with median survival of 19.2 months versus 14.7 months without SMAD4. In another cohort of 348 PDAC patients, 53% had DPC4/Smad4 expression loss.
- KRAS is the most frequently mutated gene in pancreatic cancer, reported at 90–95% in pancreatic adenocarcinomas and near 100% in PDAC in one section. The review also notes studies where KRAS mutations were found in 74.7% of EUS-FNA samples and 62.6% of ctDNA samples, and that ctDNA KRAS mutations were associated with shorter median survival.
Methods
- Narrative review of published studies on the molecular biology, prognosis and therapeutic targeting of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer.
- The paper synthesizes findings from human cohorts, TCGA/bioinformatics analyses, liquid biopsy studies, and preclinical mouse/cell line experiments.
- Main analysis is qualitative integration of reported mutation frequencies, survival associations, and treatment-response observations across the cited literature.
Limitations
- The paper does not describe a systematic review protocol, search strategy, inclusion criteria, or meta-analysis; this is evident from the text.
- The review itself notes that the prognostic impact of some markers remains unsettled, e.g. CDKN2A mutations are “still being investigated” and the impact on treatment response “requires further exploration.”
- It also states that SMAD4 effects on chemotherapy response may vary by treatment regimen and disease stage, indicating incomplete or context-dependent evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Modifiable factors include smoking, alcohol, obesity and dietary factors, where red meat increases risk, while vegetables and fruits offer protection. Non-modifiable risk factors comprise gender, age (with increased risk after 50), ethnicity, diabetes, family history, genetic factors, chronic infections and ABO blood group (non-O associated with higher risk). Created with BioRender.com (accessed on 27 February 2024) [13].](https://figures.cochat.ai/paper-figures/1e688da2d762458a9850f21c4797fbbf/significance-of-tp53-cdkn2a-smad4-and-kras-in-pancreatic-cancer-figure-1.jpg)


Verification
Claims the paper makes
106 Valid · 3 Not valid · 52 Not checked · 2 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This multifunctional protein also facilitates the activation of receptor-regulated SMADs (R-SMADs), including SMAD3 and SMAD1, highlighting its role in orchestrating downstream events [62,81].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 4. SMAD4 > 4.1. TGF-β Signaling and Tumor Suppression/Promotion
What the sources say
- Supportedcites [62] Liu, L., Li, Q., Yang, L., Li, Q., and Du, X. (2021). SMAD4 Feedback Activates the Canonical TGF-β Family Signaling Pathways. Int. J. Mol. Sci., 22. source
The Discussion states that SMAD4 induced R-SMAD activity by increasing phosphorylation in porcine granulosa cells, naming p-SMAD3 and p-SMAD1. It qualifies the evidence: p-SMAD3 was reported in a previous study, while the p-SMAD1 result was from ongoing research with data not shown. (LLM, conf=0.88)
- Disputedcites [81] Zhao, 2018, The role of TGF-β/SMAD4 signaling in cancer, Int. J. Biol. Sci. sourceExperimental — accuracy not yet measured
In “The role of SMAD4 in TGF-β signaling pathway” (page not provided), the paper identifies SMAD1 and SMAD3 as R-SMADs but describes their activation in the opposite order from the claim: the receptor phosphorylates SMAD2/3 before they form a complex with SMAD4. It describes SMAD4 as a mediator of downstream signaling, not as facilitating R-SMAD activation. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TP53 mutational status-based genomic signature emerges as a critical factor for disease prognosis and therapeutic responses.”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [21] Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., and Liu, Y. (2021). TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front. Cell Dev. Biol., 9. source
The Discussion states that the TP53-associated signature can stratify prognosis and serve as a therapeutic indicator in pancreatic cancer. The Results also say it might guide selection of chemotherapeutic agents, supporting the claim about therapeutic responses in that disease. (LLM, conf=0.91)
- Not checked yetcites [22] Liu, 2022, A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer, Math. Biosci. Eng. source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [23] Liu, X., Chen, B., Chen, J., and Sun, S. (2021). A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer. BMC Cancer, 21. sourceExperimental — accuracy not yet measured
The Results report that TP53-mutated patients had significantly worse overall survival in three pancreatic cancer cohorts, and the Discussion describes a seven-gene TP53-related signature for prognosis prediction. The cited passages do not establish that the signature predicts therapeutic responses. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genetic analysis indicates complex interactions among KRAS, CDKN2A, TP53 and SMAD4 alterations, influencing metastatic burden and survival [26].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [26] Yachida, 2012, Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors, Clin. Cancer Res. source
The Results section (page unavailable in our copy) describes patterns of coexisting KRAS, CDKN2A, TP53 and SMAD4 alterations. It reports that the number of altered driver genes was significantly correlated with metastatic burden, disease-free survival and overall survival. The claim is supported as an association; the study does not establish causation. (LLM, conf=0.91)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Pancreatic cancer commonly features mutations in key genes, such as KRAS, p16/CDKN2A, TP53 and SMAD4/DPC4 [3,4,5] (Table 1).”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [3] Maitra, 2008, Pancreatic cancer, Annu. Rev. Pathol. source
- Supportedcites [4] Saiki, Y., Jiang, C., Ohmuraya, M., and Furukawa, T. (2021). Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers, 14. source
The Introduction identifies KRAS, CDKN2A, TP53 and SMAD4 as the four main genetic drivers of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Sections 2.1, 2.4 and 2.5 further describe alterations in KRAS, SMAD4 and CDKN2A; section 2.5 identifies p16 as a CDKN2A product. (LLM, conf=0.91)
- Supportedcites [5] Hu, 2021, Mutations in key driver genes of pancreatic cancer: Molecularly targeted therapies and other clinical implications, Acta Pharmacol. Sin. source
The Introduction names KRAS, CDKN2A, TP53, and SMAD4/DPC4 as the main driver genes in pancreatic cancer. Figure 1 identifies KRAS, CDKN2A, TP53, and SMAD4 as the most commonly mutated genes in the TCGA pancreatic-cancer dataset. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The accuracy of this genomic signature is underscored by its association with the immunophenotype of PDAC [21,22,23].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [21] Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., and Liu, Y. (2021). TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front. Cell Dev. Biol., 9. source
The Discussion reports that the TP53-associated signature was an accurate, independently validated prognostic predictor and could reflect immune cell infiltration. The Results section on immune cell infiltration reports correlations between signature risk scores and specific immune-cell populations in pancreatic cancer. Together, these support the claimed association with immunophenotype, though the paper does not use the exact phrase ‘underscored by.’ No page numbers are available in our copy. (LLM, conf=0.88)
- Not checked yetcites [22] Liu, 2022, A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer, Math. Biosci. Eng. source
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites [23] Liu, X., Chen, B., Chen, J., and Sun, S. (2021). A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer. BMC Cancer, 21. source
The Results section, “Immune cell infiltration analysis and GSEA” (page unavailable), reports significant differences in immune-cell fractions between the signature’s high- and low-risk groups. The paper also reports prognostic performance for the signature; describing the immune association as underscoring its accuracy is the citing authors’ interpretation. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
66 more claims · 39 with their cited sources checked
Create a free account to see all 163 claims and to verify the 24 references still open.
- It may state two separate claims as one. 88
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 4
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“A copy number analysis revealed recurrent gains and losses, implicating genes like MET and CDKN2A [87].”
BackgroundExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 1×
“Exosomes expressing CD47 demonstrated enhanced circulation and accumulation in pancreatic tumors, effectively reducing KrasG12D mRNA levels and inhibiting tumor growth in mouse models [96].”
BackgroundEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Epidemiology of pancreatic cancer
Ilic, M., & Ilic, I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i44.9694 · Cited by 1,301
Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., Liu, C.-G., Bhatt, D., Taccioli, C., & Croce, C. M. (2007) · JAMA · doi:10.1001/jama.297.17.1901 · Cited by 1,141
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Deer, E. L., González-Hernández, J., Coursen, J. D., Shea, J. E., Ngatia, J., Scaife, C. L., Firpo, M. A., & Mulvihill, S. J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c15963 · Cited by 936 · cited 1×
“Discrepancies in the mutational status of TP53 and CDKN2A/p16 among cell lines caution researchers about discrepancies between laboratory-specific and literature-reported mutational statuses [20].”
BackgroundKRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Epidemiology of pancreatic cancer: an overview
Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.177 · Cited by 740
Regulation and function of the p53 tumor suppressor protein
Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721
Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674 · cited 1×
“However, when combined with the oncogenic KrasG12D mutation, Smad4 deletion dramatically accelerated the development of pancreatic tumors, leading to a significant reduction in survival [65].”
BackgroundMutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
The role of TGF-β/SMAD4 signaling in cancer
Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631 · cited 8×
“Furthermore, SMAD4 plays a pivotal role in the regulation of Epithelial-Mesenchymal Transition (EMT), a process with implications for cancer growth, wound healing and cancer metastasis [81].”
BackgroundInfluentialPancreatic cancer: A review of epidemiology, trend, and risk factors
Hu, J.-X., Zhao, C.-F., Chen, W.-B., Liu, Q.-C., Li, Q.-W., Lin, Y.-Y., & Gao, F. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i27.4298 · Cited by 588
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms8686 · Cited by 484 · cited 2×
“[7,8].”
BackgroundGoldstein, A. M., Chan, M., Harland, M., Gillanders, E. M., Hayward, N. K., Avril, M.-F., Azizi, E., Bianchi-Scarra, G., Bishop, D. T., Bressac-de Paillerets, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0494 · Cited by 426
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M., & Dong, Z. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.017 · Cited by 425
Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Fujitani, Y., Fujitani, S., Wright, C. V. E., & Moses, H. L. (2006) · Genes & Development · doi:10.1101/gad.1475506 · Cited by 379
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336 · cited 1×
“Furthermore, in a clinical trial involving siG12D-LODER, a sustained release siRNA matrix, in combination with chemotherapy, promising outcomes were observed, including inhibited tumor growth, reduced metastasis development and improved survival rates in patients with locally advanced PDAC [106].”
BackgroundGenetic profile of 22 pancreatic carcinoma cell lines: Analysis of K-ras, p53, p16 and DPC4/Smad4
Moore, P. S., Sipos, B., Orlandini, S., Sorio, C., Real, F. X., Lemoine, N. R., Gress, T., Bassi, C., Klöppel, G., Kalthoff, H., et al. (2001) · Virchows Archiv · doi:10.1007/s004280100474 · Cited by 329
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
(2001) · PubMed · Cited by 309
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
The CDKN2A (p16) Gene and Human Cancer
Foulkes, W. D., Flanders, T. Y., Pollock, P. M., & Hayward, N. K. (1997) · Molecular Medicine · doi:10.1007/bf03401664 · Cited by 292
Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., Haque, W., Hobbs, B. D., Krishnan, S., Fleming, J. B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8038 · Cited by 288
Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1215 · Cited by 280
Yang, S., Che, S. P. Y., Kurywchak, P., Tavormina, J. L., Gansmo, L. B., Correa de Sampaio, P., Tachezy, M., Bockhorn, M., Gebauer, F., Haltom, A. R., et al. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1281499 · Cited by 248 · cited 1×
“A study successfully detected KRASG12D and TP53R273H mutations in exosomal DNA from PDAC patients, showcasing the potential role of liquid biopsy [30].”
BackgroundRole of Smad4 (DPC4) inactivation in human cancer
Miyaki, M., & Kuroki, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01066-0 · Cited by 242
Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer
Kinugasa, H., Nouso, K., Miyahara, K., Morimoto, Y., Dohi, C., Tsutsumi, K., Kato, H., Matsubara, T., Okada, H., & Yamamoto, K. (2015) · Cancer · doi:10.1002/cncr.29364 · Cited by 239
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237 · cited 3×
“Inflammation, driven by KRAS signaling and proinflammatory cytokines, accelerates PDAC development, impacting cell survival, proliferation and metastasis [37].”
BackgroundInfluentialOshima, M., Okano, K., Muraki, S., Haba, R., Maeba, T., Suzuki, Y., & Yachida, S. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182827a65 · Cited by 236 · cited 1×
“Additionally, the loss of p16 immunolabeling was linked to distant metastases, emphasizing its association with disease progression patterns [75].”
BackgroundComparative analysis of mutations in the p53 and K‐ras genes in pancreatic cancer
Berrozpe, G., Schaeffer, J., Peinado, M. A., Real, F. X., & Perucho, M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580207 · Cited by 236
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Bournet, B., Muscari, F., Buscail, C., Assenat, E., Barthet, M., Hammel, P., Selves, J., Guimbaud, R., Cordelier, P., & Buscail, L. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.18 · Cited by 205 · cited 1×
“This association held true, even in the subgroup that received chemotherapy, highlighting the independent negative prognostic impact of the G12D KRAS mutation in unresectable pancreatic cancer [99].”
BackgroundRas Activity Levels Control the Development of Pancreatic Diseases
Ji, B., Tsou, L., Wang, H., Gaiser, S., Chang, D. Z., Daniluk, J., Bi, Y., Grote, T., Longnecker, D. S., & Logsdon, C. D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.052 · Cited by 194
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip, P. A., Azar, I., Xiu, J., Hall, M. J., Hendifar, A. E., Lou, E., Hwang, J. J., Gong, J., Feldman, R., Ellis, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3581 · Cited by 191 · cited 1×
“Additionally, KRAS WT cases showed higher microsatellite instability and tumor mutational burden, potentially making them more responsive to immune checkpoint inhibitor therapies [103].”
BackgroundKRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 187
CDKN2A Germline Mutations in Familial Pancreatic Cancer
Bartsch, D. K., Sina-Frey, M., Lang, S., Wild, A., Gerdes, B., Barth, P., Kress, R., Grützmann, R., Colombo-Benkmann, M., Ziegler, A., et al. (2002) · Annals of Surgery · doi:10.1097/00000658-200212000-00005 · Cited by 186 · cited 1×
“The association with a higher risk of developing pancreatic cancer is evident, and families with CDKN2A germline mutations may exhibit a pancreatic cancer-melanoma syndrome [40–42].”
BackgroundKanda, M., Sadakari, Y., Borges, M., Topazian, M., Farrell, J., Syngal, S., Lee, J., Kamel, I., Lennon, A. M., Knight, S., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.016 · Cited by 181 · cited 1×
“Notably, TP53 mutations were absent in pancreatic fluid samples from subjects with normal pancreas or chronic pancreatitis [27].”
BackgroundA p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179 · cited 2×
“Introducing wild-type TP53 into cancer cells could alter sensitivity to treatments [18].”
BackgroundSurvival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · cited 2×
“…as an independent prognostic biomarker for shorter overall The study proposed combined KRAS and PI3K inhibition as a therapeutic strategy for PDAC [92]. survival in chemotherapy-naive The potential therapeutic implications involve targeting both MEK and PI3K pathways in pancreatic cancer…”
BackgroundFleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M., & Xu, R. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010005 · Cited by 174 · cited 1×
“The frequent mutation of TP53 in conjunction with TGF-β /Smad4 alterations offers potential avenues for targeted interventions in pancreatic cancer [84].”
BackgroundPancreatic Cancer Epidemiology, Detection, and Management
Zhang, Q., Zeng, L., Chen, Y., Lian, G., Qian, C., Chen, S., Li, J., & Huang, K. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/8962321 · Cited by 174
KRAS Controls Pancreatic Cancer Cell Lipid Metabolism and Invasive Potential through the Lipase HSL
Rozeveld, C. N., Johnson, K. M., Zhang, L., & Razidlo, G. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1255 · Cited by 165
DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma
Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163
Wang, F., Xia, X., Yang, C., Shen, J., Mai, J., Kim, H.-C., Kirui, D., Kang, Y., Fleming, J. B., Koay, E. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3435 · Cited by 160
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Hashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149
Zhao, X., Liu, L., Lang, J., Cheng, K., Wang, Y., Li, X., Shi, J., Wang, Y., & Nie, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.042 · Cited by 136
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling
McWilliams, R. R., Wieben, E. D., Rabe, K. G., Pedersen, K. S., Wu, Y., Sicotte, H., & Petersen, G. M. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.198 · Cited by 135
Familial melanoma, pancreatic cancer and germline CDKN2A mutations
Goldstein, A. M. (2004) · Human Mutation · doi:10.1002/humu.9247 · Cited by 130
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2010.05.014 · Cited by 128 · cited 1×
“Patients with plasma KRAS mutations exhibited significantly shorter median survival times [98].”
BackgroundGenome profiling of pancreatic adenocarcinoma
Birnbaum, D. J., Adélaïde, J., Mamessier, E., Finetti, P., Lagarde, A., Monges, G., Viret, F., Gonçalvès, A., Turrini, O., Delpero, J., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20870 · Cited by 122
Shin, S. H., Kim, S. C., Hong, S.-M., Kim, Y. H., Song, K.-B., Park, K.-M., & Lee, Y.-J. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825b6ab0 · Cited by 107
Liang, C., Xu, J., Meng, Q., Zhang, B., Liu, J., Hua, J., Zhang, Y., Shi, S., & Yu, X. (2020) · Autophagy · doi:10.1080/15548627.2019.1628540 · Cited by 106
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Perets, R., Greenberg, O., Shentzer, T., Semenisty, V., Epelbaum, R., Bick, T., Sarji, S., Ben-Izhak, O., Sabo, E., & Hershkovitz, D. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0467 · Cited by 100 · cited 2×
“In the context of metastatic PDAC, detectable ctDNA has been associated with clinical outcomes, and ctDNA dynamics provided more signi fi cant prognostic information compared to the standard biomarker CA19-9 [105].”
BackgroundQiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99 · cited 1×
“Loss of the wild-type KRAS allele further promoted tumor cell proliferation and metastasis [90].”
BackgroundSomatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93 · cited 2×
“While CDKN2A aberrations alone do not significantly impact survival, concurrent mutations in both KRAS and CDKN2A are associated with the shortest survival, particularly in PDAC [52].”
BackgroundFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Caparello, C., Meijer, L. L., Garajová, I., Falcone, A., Large, T. Y. S. L., Funel, N., Geert Kazemier, M., Peters, G. J., Vasile, E., & Giovannetti, E. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.6987 · Cited by 90
Réjiba, S., Wack, S., Aprahamian, M., & Hajri, A. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00506.x · Cited by 89
Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88
Chen, Z., Guo, Y., Zhao, D., Zou, Q., Yu, F., Zhang, L., & Xu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.808208 · Cited by 87 · cited 3×
“This interaction maintains the retinoblastoma (Rb) protein in an active state, preventing G1 to S phase transition [109–111].”
BackgroundKim, H., Saka, B., Knight, S., Borges, M., Childs, E., Klein, A., Wolfgang, C., Herman, J., Adsay, V. N., Hruban, R. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1239 · Cited by 85
KRas, ROS and the initiation of pancreatic cancer
Storz, P. (2017) · Small GTPases · doi:10.1080/21541248.2016.1192714 · Cited by 82 · cited 1×
“This excess ROS triggers key signaling pathways implicated in PDAC development [122].”
BackgroundRegulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications
Jiao, Y., Feng, Y., & Wang, X. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918110019 · Cited by 81
Kazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H. R., Beato, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3399 · Cited by 81
SMAD4 feedback regulates the canonical TGF-β signaling pathway to control granulosa cell apoptosis
Du, X., Pan, Z., Li, Q., Liu, H., & Li, Q. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0205-2 · Cited by 79 · cited 1×
“For instance, SMAD4 knockdown decreases TGFBR2 mRNA expression, whereas SMAD4 overexpression increases its expression [115].”
BackgroundNorris, A. M., Gore, A., Balboni, A., Young, A., Longnecker, D. S., & Korc, M. (2013) · Oncogene · doi:10.1038/onc.2012.394 · Cited by 79
SMAD4 activates Wnt signaling pathway to inhibit granulosa cell apoptosis
Du, X., Li, Q., Yang, L., Liu, L., Cao, Q., & Li, Q. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2578-x · Cited by 76 · cited 2×
“Dysregulation of SMAD4 is associated with various aspects of cancer progression, encompassing autophagy, invasion and metastasis, under-scoring its significance in cellular responses and disease [114].”
BackgroundMutations of p53 associated with pancreatic cancer and therapeutic implications
Voutsadakis, I. A. (2021) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2021.25.3.315 · Cited by 75
Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis
Shugang, X., Hongfa, Y., Jianpeng, L., Xu, Z., Jingqi, F., Xiangxiang, L., & Wei, L. (2016) · Translational Oncology · doi:10.1016/j.tranon.2015.11.007 · Cited by 72
SMAD4 Expression Predicts Local Spread and Treatment Failure in Resected Pancreatic Cancer
Yamada, S., Fujii, T., Shimoyama, Y., Kanda, M., Nakayama, G., Sugimoto, H., Koike, M., Nomoto, S., Fujiwara, M., Nakao, A., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000315 · Cited by 71
McCarthy, A. J., & Chetty, R. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205095 · Cited by 71
High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival
Wang, Q., Ni, Q., Wang, X., Zhu, H., Wang, Z., & Huang, J. (2015) · Medical Oncology · doi:10.1007/s12032-014-0372-2 · Cited by 70 · cited 2×
“Furthermore, exosomal DNA analysis reveals high RAB27A, and TP53 expression independently associates with poor overall survival [25].”
BackgroundJäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01118-x · Cited by 69
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
Hofmann, I., Weiss, A., Elain, G., Schwaederle, M., Sterker, D., Romanet, V., Schmelzle, T., Lai, A., Brachmann, S. M., Bentires-Alj, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044146 · Cited by 69
Schultz, N. A., Roslind, A., Christensen, I. J., Horn, T., Høgdall, E., Pedersen, L. N., Kruhøffer, M., Burcharth, F., Wøjdemann, M., & Johansen, J. S. (2012) · Pancreas · doi:10.1097/mpa.0b013e31823cd9df · Cited by 68
Tu, Q., Hao, J., Zhou, X., Yan, L., Dai, H., Sun, B., Yang, D., An, S., Lv, L., Jiao, B., et al. (2018) · Oncogene · doi:10.1038/onc.2017.316 · Cited by 66
The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer
Kimura, H., Klein, A. P., Hruban, R. H., & Roberts, N. J. (2021) · Pancreas · doi:10.1097/mpa.0000000000001888 · Cited by 65
Tang, B., Li, Y., Qi, G., Yuan, S., Wang, Z., Yu, S., Li, B., & He, S. (2015) · Scientific Reports · doi:10.1038/srep13563 · Cited by 64
Shin, S. H., Kim, H. J., Hwang, D. W., Lee, J. H., Song, K. B., Jun, E., Shim, I. K., Hong, S.-M., Kim, H. J., Park, K.-M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14901 · Cited by 57 · cited 1×
“Notably, SMAD4 loss is associated with distant metastases, highlighting its role in disease progression patterns [72–76 , 118 ].”
BackgroundMultifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49 · cited 2×
“…in fl uencing mRNA degradation mechanisms [36]. variants, alter tumor microenvironment, promoting proliferation and chemotherapy resistance [34, Cases with TP53 mutations often co-occur These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment,…”
BackgroundCDKN2A inhibits formation of homotypic cell-in-cell structures
Liang, J., Fan, J., Wang, M., Niu, Z., Zhang, Z., Yuan, L., Tai, Y., Chen, Z., Song, S., Wang, X., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0056-4 · Cited by 49
SMAD4 Feedback Activates the Canonical TGF-β Family Signaling Pathways
Liu, L., Li, Q., Yang, L., Li, Q., & Du, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810024 · Cited by 47 · cited 2×
“Moreover, SMAD4 engages in a feedback loop by activating the transcription of its upstream receptors, thus maintaining pathway sensitivity [62].”
BackgroundLoss of SMAD4 protein expression in gastrointestinal and extra‐gastrointestinal carcinomas
Ritterhouse, L. L., Wu, E. Y., Kim, W. G., Dillon, D. A., Hirsch, M. S., Sholl, L. M., Agoston, A. T., Setia, N., Lauwers, G. Y., Park, D. Y., et al. (2019) · Histopathology · doi:10.1111/his.13894 · Cited by 47
Lin, J.-C., Liu, T.-P., & Yang, P.-M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124019 · Cited by 46
Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
Saiki, Y., Jiang, C., Ohmuraya, M., & Furukawa, T. (2021) · Cancers · doi:10.3390/cancers14010071 · Cited by 38
Abrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.06.002 · Cited by 36
Principe, D. R., Underwood, P. W., Kumar, S., Timbers, K. E., Koch, R. M., Trevino, J. G., Munshi, H. G., & Rana, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806963 · Cited by 35
Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells
Wan, R., Feng, J., & Tang, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s297855 · Cited by 35
Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas
Harinck, F., Kluijt, I., van der Stoep, N., Oldenburg, R. A., Wagner, A., Aalfs, C. M., Sijmons, R. H., Poley, J.-W., Kuipers, E. J., Fockens, P., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100563 · Cited by 34 · cited 1×
“In FPC families, CDKN2A mutations were identified in 21.4% of cases, and in patients with both pancreatic adenocarcinoma and melanoma, germline CDKN2A mutations (I49S and M53I) were found, with I49S showing impaired binding to CDK4 [45,46].”
BackgroundInfluentialIs there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 33
Fei, N., Wen, S., Ramanathan, R., Hogg, M. E., Zureikat, A. H., Lotze, M. T., Bahary, N., Singhi, A. D., Zeh, H. J., & Boone, B. A. (2021) · Clinical and Translational Science · doi:10.1111/cts.13029 · Cited by 31 · cited 1×
“While SMAD4 loss is associated with poor prognosis and shorter survival, its impact on chemotherapy response may vary, based on specific treatment regimens and disease stages [64,70,71].”
BackgroundComprehensive tumor molecular profile analysis in clinical practice
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Mariatou, V.-M., Tsaousis, G., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00952-9 · Cited by 30
Xiong, W., He, W., Wang, T., He, S., Xu, F., Wang, Z., Wang, X., Guo, H., Ling, J., Zhang, H., et al. (2022) · Advanced Science · doi:10.1002/advs.202103029 · Cited by 29
Clinical Significance of the KRAS Mutation
Beganovic, S. G. (2010) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2009.2749 · Cited by 28
Gu, Y., Ji, Y., Jiang, H., & Qiu, G. (2020) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0078 · Cited by 28 · cited 1×
“Re-markably, TP53 overexpression correlates with shorter overall survival (OS) [24].”
BackgroundZhang, D., Wang, T., Zhou, Y., & Zhang, X. (2023) · Medicine · doi:10.1097/md.0000000000033468 · Cited by 28
SMAD4 Y353C promotes the progression of PDAC
Wang, Z., Li, Y., Zhan, S., Zhang, L., Zhang, S., Tang, Q., Li, M., Tan, Z., Liu, S., & Xing, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-6251-7 · Cited by 25 · cited 3×
“While SMAD4 loss is associated with poor prognosis and shorter survival, its impact on chemotherapy response may vary, based on specific treatment regimens and disease stages [64,70,71].”
BackgroundA novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer
Liu, X., Chen, B., Chen, J., & Sun, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08066-2 · Cited by 24 · cited 1×
“The accuracy of this genomic signature is underscored by its association with the immunophenotype of PDAC [21–23].”
BackgroundMasugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.323 · Cited by 23
Kimura, H., Paranal, R. M., Nanda, N., Wood, L. D., Eshleman, J. R., Hruban, R. H., Goggins, M. G., Klein, A. P., The Familial Pancreatic Cancer Genome Sequencing Project, & Roberts, N. J. (2022) · eLife · doi:10.7554/elife.71137 · Cited by 23
Xu, J.-Z., Wang, W.-Q., Zhang, W.-H., Xu, H.-X., Gao, H.-L., Zhang, S.-R., Wu, C.-T., Li, S., Li, H., Xu, J., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30883 · Cited by 19 · cited 1×
“The study proposed the loss of SMAD4 in conjunction with an activated Shh pathway as a predictive factor for prognosis in PDAC, emphasizing the potential clinical significance of this molecular profiling in patient counseling and disease management [80].”
BackgroundAmintas, S., Fernandez, B., Chauvet, A., Chiche, L., Laurent, C., Belleannée, G., Marty, M., Buscail, E., & Dabernat, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-07004-x · Cited by 17
Cost‐effectiveness of pancreas surveillance: The CDKN2A ‐p16‐ Leiden cohort
Ibrahim, I. S., Vasen, H. F. A., Wasser, M. N. J. M., Feshtali, S., Bonsing, B. A., Morreau, H., Inderson, A., de Vos tot Nederveen Cappel, W. H., & van den Hout, W. B. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12360 · Cited by 17
Voutsadakis, I. A., & Digklia, A. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-108 · Cited by 16
Liu, Y., Department of Colorectal and Anal Surgery, T. F. H. O. J. U., Cheng, L., Song, X., Li, C., Zhang, J., Wang, L., Department of Orthopedics, T. F. H. O. J. U., & Department of Hepatobiliary and Pancreatic Surgery, T. F. H. O. J. U. (2022) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2022010 · Cited by 14
The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma.
Doyle, A., Kubler, M. M., Harris, A. C., López, A., Govindaraj, P., Prins, P., & Weinberg, B. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.278 · Cited by 13
Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., & Liu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665265 · Cited by 13 · cited 2×
“The accuracy of this genomic signature is underscored by its association with the immunophenotype of PDAC [21–23].”
BackgroundMcCubrey, J. A., Meher, A. K., Akula, S. M., Abrams, S. L., Steelman, L. S., LaHair, M. M., Franklin, R. A., Martelli, A. M., Ratti, S., Cocco, L., et al. (2022) · Aging · doi:10.18632/aging.204038 · Cited by 12 · cited 1×
“In mouse models, intact p53 protects against pancreatic cancer progression, confirming its role in suppressing malignant transformation [17,29,36].”
BackgroundPersonalized therapy for pancreatic cancer: Myth or reality in 2010?
Huang, T.-C. J., Kar, S., & Javle, M. M. (2010) · PubMed · doi:10.3978/j.issn.2078-6891.2010.009 · Cited by 7
Ungefroren, H., Konukiewitz, B., Braun, R., Wellner, U. F., Keck, T., & Marquardt, J.-U. (2023) · Cancers · doi:10.3390/cancers15030581 · Cited by 3 · cited 1×
“Notably, SMAD4 loss is associated with distant metastases, highlighting its role in disease progression patterns [72–76 , 118 ].”
BackgroundVaske, C. J., Garner, C., Seery, T. E., Szeto, C., & Reddy, S. K. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.287 · Cited by 1
(2000) · doi:10.1002/(sici)1098-2264(200004)27:4
Jiao, Y., Feng, Y., & Wang, X. (2018) · Биохимия · doi:10.1134/s0320972518110015
Research works printed but not linked: 2
- (2023, December 26). CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo Sapiens (Human)], Available online: https://www.ncbi.nlm.nih.gov/gene/1029.
- Lovely, 2023, Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer, Oncol. Live, 24, 12
Cited by
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 131
Early Detection of Pancreatic Cancer: Current Advances and Future Opportunities
Lin, Z., Adeniran, E. A., Cai, Y., Qureshi, T. A., Li, D., Gong, J., Li, J., Pandol, S. J., & Jiang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13071733 · Cited by 47
Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 39
Dahiya, D. S., Malik, S., Paladiya, R. D., Ahsan, S., Waseem, H., Bharadwaj, H. R., Goel, A., Jaan, A., Hayat, U., Hasan, F., et al. (2025) · Cancers · doi:10.3390/cancers17071085 · Cited by 23
Graham, S., Dmitrieva, M., Costa, D. B. V., Francescone, R., Trujillo, M. A. M., Cukierman, E., & Wood, L. D. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae064 · Cited by 19
Metadata
- Authors
- Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- University of California, Los Angeles (US)
- Corresponding author
- Toutouzas, Konstantinos G.
- ORCID
- Venue
- Current Issues in Molecular Biology
- Publisher
- MDPI AG
- Published
- 2024-03-23
- Volume
- 46
- Issue
- 4
- Pages
- 2827-2844
- ISSN
- 1467-3037 (ISSN-L)
- 1467-3045
- PMC
- PMC11049225
- OpenAlex
- W4393164529
- Cited by
- 110
- References
- 128
- Citations by year
- 2026: 55 · 2025: 42 · 2024: 13
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Issues in Molecular Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic cancer, TP53, CDKN2A, SMAD4, KRAS, tumor suppressor, p53 deficiency, prognostic value, targeted therapy, molecular signatures, cancer risk assessment, early detection, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.